Literature DB >> 241082

Effects of ganglionic and beta-adrenergic blockade on cardiovascular responses to the bisenoic prostaglandins and their precursor arachidonic acid.

P A Kot, M Johnson, P W Ramwell, J C Rose.   

Abstract

Arachidonic acid (AA) 300 mug/kg, and PGE2, 5 mug/kg consistently produced a decrease in systemic arterial pressure in anesthetized dogs. PGF2alpha, 5 mug/kg, produced a pressor response. All three compounds increased myocardial contractile force, but the magnitude of the change following AA was less prominent. After ganglionic blockade, the depressor response to AA and PGE2 persisted and the pressor response to PGF2alpha was augmented. Myocardial contractile force did not increase following AA in ganglion-blocked animals indicating that the cardiac responses observed before hexamethonium were mediated by the baroreceptor reflexes. A much larger dose of AA (900 mug/kg) resulted in a small positive inotropic effect on the heart. This possibly represents a direct cardiac effect of AA, or may be indicative of increased biosynthesis of an intermediate endoperoxide, or PGE2 and PGF2alpha. Both PGE2 and PGF2alpha have a direct positive inotropic effect on the heart. The persist cardiac effects of PGE2 and PGF2 after beta-adrenergic blockade suggests that these compounds may not interact with the beta-receptors of the myocardium.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 241082     DOI: 10.3181/00379727-149-38934

Source DB:  PubMed          Journal:  Proc Soc Exp Biol Med        ISSN: 0037-9727


  2 in total

1.  Circulatory effects of prostaglandin endoperoxide analogues studied in the dog during left ventricular bypass.

Authors:  I Alter; P A Kot; P W Ramwell; J C Rose; M R Shnider
Journal:  Br J Pharmacol       Date:  1977-11       Impact factor: 8.739

2.  Some direct and reflex cardiovascular actions of prostacyclin (PGI2) and prostaglandin E2 in anaesthetized dogs.

Authors:  D J Chapple; G J Dusting; R Hughes; J R Vane
Journal:  Br J Pharmacol       Date:  1980-03       Impact factor: 8.739

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.